Results 91 to 100 of about 79,249 (245)
Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. [PDF]
PurposeThe goal of the present study was to determine the efficacy of temozolomide (TEM) and pazopanib (PAZ) combined with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) on a colorectal cancer patient-derived orthotopic xenograft (PDOX) mouse model ...
Bouvet, Michael +9 more
core
In advanced colorectal cancer, tumors with mature tertiary lymphoid structures (TLS) exhibited abundant infiltration of CD3‐ and CD8‐positive lymphocytes in both primary and metastatic sites, indicating an activated immune response. The presence of mature TLS was also associated with favorable chemotherapy sensitivity and improved prognosis.
Nobuhiro Hosoi +9 more
wiley +1 more source
Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5‐Fluorouracil/Levo‐Leucovorin for Pancreatic Cancer [PDF]
ABSTRACT Background Nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil (5‐FU)/levo‐leucovorin (Levo‐LV) therapy is recommended as the standard of care for unresectable locally advanced (UR‐LA) and metastatic pancreatic cancer after failure of gemcitabine‐containing regimens.
Wakabayashi A +7 more
europepmc +2 more sources
Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan. [PDF]
The topoisomerase I (TOP1) inhibitor irinotecan triggers cell death by trapping TOP1 on DNA, generating cytotoxic protein-linked DNA breaks (PDBs). Despite its wide application in a variety of solid tumors, the mechanisms of cancer cell resistance to ...
Adam Hodgson +18 more
core +2 more sources
This systematic review and meta‐analysis evaluated the role of primary tumor resection (PTR) in asymptomatic patients with unresectable metastatic colorectal cancer. Across 17 eligible studies including 9317 patients, PTR did not improve overall or progression‐free survival compared with chemotherapy alone.
Junpei Takashima +3 more
wiley +1 more source
Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. [PDF]
Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic ...
Beckman, Robert A. +8 more
core +1 more source
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited [PDF]
The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-angiogenic cancer therapy are major issues in almost all current concepts of both cancer biology and targeted cancer therapy. Currently, (1) sprouting angiogenesis, (2)
Dumont, Daniel J. +2 more
core +1 more source
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa +12 more
wiley +1 more source
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response [PDF]
Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide. Despite recent progress, the prognosis of advanced stage CRC remains poor, mainly because of cancer recurrence and metastasis.
Biffoni, Mauro +9 more
core +1 more source
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source

